About Investsud
Investsud is a venture capital firm founded in 1985. It is primarily based out of Marche en Famenne, Belgium. As of Jan 2026, Investsud is an active investor, having invested in 28 companies, with 1 new investment in the last 12 months. It primarily invests in Seed round in Belgium based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and High Tech. Most recently it participated in the $***** Seed round of Enodia Therapeutics Overall, Investsud portfolio has seen 1 IPO and 1 acquisition, namely DeuterOncology and TheraVet. A lot of funds co-invest with Investsud, with names like Noshaq sharing a substantial percentage of its portfolio. Investsud has team of 14 people including 7 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Rounds of Entry
Series A, Seed & 2 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
Investsud's List of Top Investments
Investsud has a portfolio of 28 companies. Their most notable investments are in Samabriva and Myocene.Their portfolio spans across Belgium and France. They have invested in Life Sciences, HealthTech, High Tech and 10 other sectors, across stages such as Series A, Seed and 2 more. Here is the list of top investments by Investsud:Developer of immunotherapy for the treatment of cancer. The company's flagship product includes STC-1010 which is used to treat metastatic colorectal cancer (mCRC) and solid cancers.
Key facts about Brenus Pharma
- Founded Year: 2020
- Location: Issoire (France)
- Stage: Series A
- Total Funding till date: $43.4M
- Employee Count: 31 as on Aug 31, 2026
- Investors: UI Investissement, Credit Agricole and 8 Others
- Latest Funding Round: Series A, Jul 21, 2026, $*****
- Highlight: Editors' Pick
2. Novadip
Developer of stem cell-based therapies for bone healing disorders and bone defects. The company has developed regenerative therapeutics which include NVD-X3 for hard tissue reconstruction and NVD-X2 for soft tissue reconstruction. The m3 platform technology creost is a 3D osteogenic structure from autologous adipose-derived stem cells which reconstruct critical size bone defects without the use of any scaffold.
Key facts about Novadip
- Founded Year: 2013
- Location: Mont Saint Guibert (Belgium)
- Annual Revenue: €0 - €1M as on Dec 31, 2021
- Stage: Series B
- Total Funding till date: $99M
- Employee Count: 58 as on Sep 30, 2026
- Investors: SFPI, European Investment Bank and 16 Others
- Latest Funding Round: Series B, Sep 21, 2026, $*****
- Highlight: Editors' Pick
3. Bioxodes
Developer of novel peptide therapies for prevention of thrombosis. The Company’s lead programme, Ir-CPI, is being developed for the prevention of thrombosis in a range of applications including cardiopulmonary bypass grafting and percutaneous coronary intervention.
Key facts about Bioxodes
- Founded Year: 2013
- Location: Marche en Famenne (Belgium)
- Stage: Series A
- Total Funding till date: $45.4M
- Employee Count: 12 as on Sep 30, 2026
- Investors: SFPI, Newton Biocapital and 3 Others
- Latest Funding Round: Series A, Dec 10, 2025, $*****
- Highlight: Editors' Pick
ATB Therapeutics is developing mAb-based therapy in oncology. The company aims to generate a pipeline of assets for hematological and solid cancers. The company is currently entering in preclinical stage.
Key facts about ATB Therapeutics
- Founded Year: 2017
- Location: Marche en Famenne (Belgium)
- Stage: Series A
- Total Funding till date: $56.9M
- Employee Count: 38 as on Aug 31, 2026
- Investors: EQT, Vives Fund and 8 Others
- Latest Funding Round: Series A, Nov 18, 2024, $*****
- Highlight: Editors' Pick
Developer of therapeutic solutions for treating immunological disorders. The company's proprietary platform aims to develop an anti-CD45RC monoclonal antibody to deplete effector T cells, preserve regulatory and memory T cells. It induces immune tolerance and preserves immune responses in inflammatory, autoimmune, and degenerative diseases. It has also developed an IL-34 cytokine that helps to induce tolerogenic macrophages.
Key facts about AbolerIS Pharma
- Founded Year: 2019
- Location: Nantes (France)
- Stage: Series A
- Total Funding till date: $32M
- Employee Count: 13 as on Aug 31, 2026
- Investors: Newton Biocapital, Wallonie Entreprendre and 8 Others
- Latest Funding Round: Series A, Sep 18, 2023, $*****
- Highlight: Editors' Pick
Investsud's Year-on-Year Investment Trends
Investsud has invested in 28 companies over the last 10 years, with an average of 2 new investments annually in the last 10 years. In 2025, it made 2 investments, while as of Jan 2026, it has made 1 investment in this year. Its most recent first time investment was in Enodia Therapeutics and most recent follow-on round was in Synergia Medical.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 1 | 0 | 1 |
2025 | 2 | 0 | 2 |
2024 | 2 | 0 | 2 |
2023 | 5 | 1 | 6 |
2022 | 0 | 1 | 1 |
2021 | 2 | 0 | 2 |
2020 | 0 | 0 | 0 |
2019 | 0 | 0 | 0 |
2018 | 2 | 0 | 2 |
Investsud's Investments by Stage
Investsud has made 8 investments in Series A stage with an average round size of $13.5M, 5 investments in Seed stage with an average round size of $8.03M, 1 investment in Series B stage with an average round size of $22M and 1 investment in Series C stage with an average round size of $29M.Stage of entry | No. of Investments |
|---|---|
Series A | 8 |
Seed | 5 |
Series B | 1 |
Series C | 1 |
Note: We have considered here, only first round of investments
Investsud's Investments by Sector
Investsud has a diverse portfolio, with companies operating in the Life Sciences, Consumer, HealthTech, High Tech and Enterprise Applications. Notably, it has invested in 17 Tech companies, 15 Enterprise (B2B) companies, 4 Software companies and at least 4 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 11 |
Consumer | 2 |
HealthTech | 2 |
High Tech | 2 |
Enterprise Applications | 1 |
Others | 3 |
Note: We have considered here, only first round of investments
Investsud's Investments by Geography
Investsud has made most investments in Belgium (9), followed by France where it has made 5 investments.Country | No. of Investments |
|---|---|
Belgium | 9 |
France | 5 |
Note: We have considered here, only first round of investments
Investsud's recent investments
Investsud has made 1 investments in 2026 so far - Enodia Therapeutics.Here are the most recent investments by Investsud:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jan 08, 2026 | France | Seed | 6672 | [+8] | |
Sep 25, 2025 | Belgium | Series C | 1571 | [+11] | |
Jan 15, 2025 | - | Series A | 6786 | ||
Sep 18, 2024 | France | Series A | 4107 | [+2] | |
Jun 18, 2024 | Belgium | Seed | 9102 |
IPOs and Publicly Listed companies in Investsud's Portfolio
1 of Investsud's portfolio company became public - TheraVet. It got listed on the Euronext Exchange (Euronext), in Jun 2021 at marketcap of $37.1MHere are Investsud's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jun 17, 2021 | - | - | 1298 |
Acquired companies in Investsud's Portfolio
1 company from Investsud's portfolio has been acquired. The most recent acquisition was DeuterOncology in May 2026 by Pathos for $*****.Here are Investsud's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
May 06, 2026 | Jan 19, 2023 | Series A | 5295 |
Team profile of Investsud
Investsud has a team of 14 members including 7 Partners located in Belgium and Marche. Investsud's team does not sit on the board of any company as of now.Here is a list of top team members in Investsud:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Belgium | - | ||
Partner | Belgium | - | ||
Partner | Namur | - | - | |
Partner | Belgium | - | ||
Partner | Marche | - | - | |
Partner | Belgium | - | - | |
Partner | Belgium | - | - |
Co-investors of Investsud
Over the past 10 years, 92 investors have co-invested in Investsud's portfolio companies. This includes funds and angels.
- Invested before Investsud: Vives Fund, Europa and 20 others have invested in rounds before Investsud. There are 2 companies where Vives Fund has invested before Investsud and 2 companies where Europa has invested before Investsud.
- Top Co-investors of Investsud: 36 investors entered a company along with Investsud. These include investors like Noshaq (6 companies).
- Invested after Investsud: A total of 34 investors have invested in Investsud's portfolio after their investments. Top Investors include Sambrinvest (3 companies), Pierre Drion (2 companies) and Credit Agricole (1 company).
Recent News related to Investsud
•
Enodia Therapeutics Raises €20.7M in Seed FundingFinSMEs•Jan 08, 2026•Wallonie Entreprendre, Bpifrance, Pasteur Institute, MACSF and 7 others
•
Sunrise Group Secures $29M to Expand Dreem Health Sleep Clinic Across the U.S.HIT Consultant•Sep 25, 2025•Dreem Health, Sunrise Enterprises, Eurazeo, Amazon and 12 others
•
Myocene scores €3M to expand AI-based muscle fatigue-monitoring device for athletesTech Funding News•Jun 18, 2024•Myocene, Investsud, Wallonie Entreprendre, Noshaq
•
Samabriva will become a global leader in precision biomanufacturing of complex molecules with the announcement of a €4 million financing roundBusiness Wire•Dec 12, 2023•Samabriva, Noshaq, Investsud, Wallonia
•
Belgium-based Cikisi raises €2.7M to expand its market intelligence toolSilicon Canals•Sep 01, 2023•Cikisi, Sambrinvest, Investsud, Finnance.brussels and 1 other
•
DeuterOncology Closes €5.65M Series A Financing RoundFinSMEs•Jan 19, 2023•DeuterOncology, Newton Biocapital, Noshaq, Investsud
•
Novadip Biosciences Raises Additional EUR 40 Million Bringing Total Company Funding to EUR 88 MillionBusiness Wire•Nov 03, 2022•Novadip, New Science Ventures, Fund+, SRIW and 6 others
•
NeuVasQ Biotechnologies bags €20m in Series A financingEuropean Biotechnology•Jun 22, 2021•Newton Biocapital, SFPI, SRIW, Sambrinvest and 1 other
•
Korean VCs pile into PDC*line to bankroll NSCLC vaccine trialFierce Biotech•Jan 22, 2020•PDC*line Pharma, SRIW, Sambrinvest, Korea Investment Partners and 5 others
